- Home
- SRRK vs TERN Comparison
SRRK vs TERN Comparison
Compare SRRK & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRRK | TERN |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | 289 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.8B |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SRRK | TERN |
|---|---|---|
| Price | $40.03 | $46.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $55.10 | $48.60 |
| AVG Volume (30 Days) | 1.1M | ★ 1.5M |
| Earning Date | 05-28-2026 | 04-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.81 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $449.79 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.71 | $1.87 |
| 52 Week High | $49.82 | $48.26 |
Technical Indicators
Market Signals| Indicator | SRRK | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 32.95 | 68.68 |
| Support Level | $29.32 | $38.99 |
| Resistance Level | $42.54 | $48.26 |
| Average True Range (ATR) | 2.24 | 2.40 |
| MACD | -0.62 | 0.37 |
| Stochastic Oscillator | 1.77 | 89.09 |
Price Performance
Historical ComparisonAbout SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
About TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.